Trade Vir Biotechnology VIR

Sell
 Buy

VirBiotechnology live chart

5m 15m 30m 1h 4h 1d 1w

instrument_fundamentals

Weekly Search
Weekly
Daily
date Close change Change (%) instr__open High Low

instr__news

Webhose 2026 Jan 29, 22:31

Chronic Hepatitis D Market Poised for Significant Growth During the Forecast Period (2025-2034) as Emerging Therapies Drive Optimism | DelveInsight

Vir Biotechnology Inc
Webhose 2026 Jan 26, 00:27

Vir Biotechnology (VIR) Is Up 24.8% After Strong SOLSTICE Combo Data In Hepatitis Delta Trial - Has The Bull Case Changed?

Vir Biotechnology Inc
Webhose 2026 Jan 23, 15:08

Vir Biotechnology (VIR) Is Up 19.4% After Strong Dual-Therapy Data in Hepatitis Delta Trial

Vir Biotechnology Inc
Webhose 2026 Jan 23, 12:15

Vir Biotechnology, Inc. (NASDAQ:VIR) Given Average Recommendation of "Moderate Buy" by Brokerages

Vir Biotechnology Inc
Webhose 2026 Jan 23, 09:40

A Look At Vir Biotechnology (VIR) Valuation After New SOLSTICE Trial Data And Pipeline Updates

Vir Biotechnology Inc
Webhose 2026 Jan 21, 20:33

Vir Biotechnology (NASDAQ:VIR) Shares Up 9.9% - Should You Buy?

Vir Biotechnology Inc
Webhose 2026 Jan 20, 19:00

Reviewing Vir Biotechnology (NASDAQ:VIR) and Creative Medical Technology (NASDAQ:CELZ) - Stock Observer

Vir Biotechnology Inc
Webhose 2026 Jan 13, 22:38

Vir Biotechnology (NASDAQ:VIR) Trading 7.3% Higher - What's Next?

Vir Biotechnology Inc
Webhose 2026 Jan 13, 14:38

Vir Biotechnology (NASDAQ:VIR) Trading Up 7.3% - Should You Buy? - Daily Political

Vir Biotechnology Inc
Webhose 2026 Jan 08, 02:26

Vir Biotechnology (NASDAQ:VIR) Director Sells $130,460.00 in Stock - Daily Political

Vir Biotechnology Inc
Webhose 2026 Jan 05, 21:10

Company Website: https://vir.bio SAN FRANCISCO -- (Busines

Vir Biotechnology Inc
Webhose 2026 Jan 05, 20:45

Vicki Sato Sells 22,000 Shares of Vir Biotechnology (NASDAQ:VIR) Stock

Vir Biotechnology Inc

VirBiotechnology news

Latest news

Show more

Info

Spread

0.05

Spread (%)

0.8446 %

Leverage

1:10

Overnight Interest Buy

-0.0597 %

Overnight Interest Sell

-0.0292 %

Currency

USD

Trading Hours

Markets closed

Friday

14:31 - 20:59

Monday

14:31-20:59

Tuesday

14:31-20:59

Wednesday

14:31-20:59

Thursday

14:31-20:59

instr__analysis_statistics

instr__open

---

instr__close

---

instr__52week_range

--- – ---

instr__market_cap

1072653952

instr__shares_outstand

139125032

instr__earnings_date

0000-00-00

instr__dividend_date

instr__ex_dividend_date

instr__forward_annual_dividend_rate

0

instr__forward_annual_dividend_yield

0

instr__eps

-3.62

instrument_learn_more

Vir Biotechnology Vir Biotechnology Inc
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). It has grant agreements with Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

related_instruments

Asset
Sell
Buy
Change (%)

trade_now_btn

trade_now_btn

trade_now_btn

trade_now_btn
view_all_instruments

latest_education_articles

Show more
Trustpilot